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Abstract
Background: For patients with diabetes, clinical practice guidelines recommend treating to a low-density
lipoprotein cholesterol (LDL-C) goal of <2.59 mmol/L (100 mg/dL) and a blood pressure (BP) target of <130/80
mmHg. This analysis assessed recent trends in the utilization of lipid-lowering and BP-lowering agents, as well as
LDL-C and BP goal attainment, in the U.S. adult diabetic population.
Methods: 9,167 men and nonpregnant women aged ≥20 years were identified from the fasting subsample of the
1999-2008 National Health and Nutritional Examination Survey. Diabetes was identified in 1,214 participants by self
report, self-reported use of insulin or oral medications for diabetes, or fasting glucose ≥6.99 mmol/L (126 mg/dL).
Results: The prevalence of diagnosed or undiagnosed diabetes increased significantly over the past decade, from
7.4% in 1999-2000 to 11.9% in 2007-2008 (P = 0.0007). During this period, the use of lipid-lowering agents by
participants with diabetes increased from 19.5% to 42.2% (P < 0.0001), and the proportion at LDL-C goal increased
from 29.7% to 54.4% (P < 0.0001). Although there was a significant increase in antihypertensive medication use
(from 35.4% to 58.9%; P < 0.0001), there was no significant change in the proportion of participants at BP goal
(from 47.6% to 55.1%; P = 0.1333) or prevalence of hypertension (from 66.6% to 74.2%; P = 0.3724).
Conclusions: The proportion of diabetic individuals taking lipid- and BP-lowering agents has increased significantly
in recent years. However, while there has been a significant improvement in LDL-C goal attainment, nearly one-half
of all U.S. adults with diabetes are not at recommended LDL-C or BP treatment goals.
Background
An estimated 18.8 million Americans have a diagnosis of
diabetes, and a further 7 million have undiagnosed dia-
betes [1]. A recent analysis including diagnosed diabetes,
undiagnosed diabetes, and pre-diabetes indicates that
>40% of the U.S. adult population has some form of
hyperglycemia [2]. The economic burden associated
with diabetes is substantial: the total cost attributable to
recognized diabetes in the U.S. in 2007 was estimated at
$174 billion [3].
Cardiovascular (CV) complications are the major con-
tributors to morbidity and mortality in patients with
diabetes [4]. The risk of mortality from cardiovascular
disease (CVD) is increased by up to 5-fold in patients
with diabetes [5-7]. Although debated within the
literature, the National Cholesterol Education Program
Adult Treatment Panel III has classified diabetes as a
coronary heart disease (CHD) risk equivalent [8,9]. Dys-
lipidemia and hypertension are independent predictors
of future CV events, and clinical interventions that tar-
get these risk factors have been shown to reduce CV
outcomes in patients with diabetes [10-16]. As such,
aggressive control of modifiable CV risk factors is parti-
cularly important in this high-risk population.
Current national treatment guidelines for patients with
diabetes [4] advocate a low-density lipoprotein choles-
terol (LDL-C) goal of <2.59 mmol/L (100 mg/dL), with
an optional goal of <1.81 mmol/L (70 mg/dL) in those
with overt CVD, and a blood pressure (BP) goal of
<130/80 mmHg. With respect to lipid-lowering therapy,
treatment recommendations include the use of statins in
addition to lifestyle modification to improve lipid pro-
files. For diabetic patients with overt CVD, or those
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risk factor, statin therapy is recommended irrespective
of baseline lipid levels.
Using National Health and Nutritional Examination
Survey (NHANES) data covering the period 1999-2008,
this analysis of the U.S. adult diabetic population
assessed recent trends in the utilization of lipid-lowering
and antihypertensive agents, as well as LDL-C and BP
goal attainment rates.
Research design and methods
Study design
NHANES is conducted by the National Center of Health
Statistics, Centers for Disease Control and Prevention,
as a cross-sectional, stratified, multistage probability
s a m p l es u r v e yo ft h eU . S .c i v i l ian, noninstitutionalized
population [17,18]. NHANES data are derived from
direct interviews regarding medical history, medication
use, and diet, as well as clinical examinations (including
BP measurements) and laboratory tests (including lipid
and glucose blood biochemistries). From 1999,
NHANES became a continuous survey, and data are
released in 2-year increments. This analysis used data
from the 5 most recent study cycles: 1999-2000, 2001-
2002, 2003-2004, 2005-2006, and 2007-2008. NHANES
1999-2008 received approval from the National Center
for Health Statistics research ethics review board, and
written informed consent was obtained from all
NHANES participants [17].
Sample population
A total of 9,167 men and nonpregnant women ≥20 years
of age with valid data on their diabetic status, in addi-
tion to complete lipid and BP data, were identified from
the fasting subsample (n = 16,675) of the 1999-2008
NHANES population. NHANES participants are ran-
domly selected for inclusion in the fasting subsample
and instructed to fast for 8 to <24 hours prior to blood
specimens being taken for laboratory testing [18]. Pre-
sence of diagnosed or undiagnosed diabetes in a subset
of 1,214 participants was identified by self report of dia-
betes, self-reported use of insulin or oral medications
for diabetes, or a fasting plasma glucose ≥6.99 mmol/L
(126 mg/dL).
Data collection and laboratory measurements
All drug utilization and disease history was self-reported.
BP measurements in NHANES were performed 3-4
times manually with a mercury sphygmomanometer
according to a standard protocol [18]; the first reading
was excluded and remaining readings used to compute
average BP. Hypertension was defined as an average BP
>130 mmHg systolic or >80 mmHg diastolic, or self-
reported use of antihypertensive agents.
Methods for determining blood lipid and glucose
levels in NHANES have been described [18]. Briefly,
total cholesterol was measured enzymatically on the
basis of hydrogen peroxide generation. In 1999-2002,
high-density lipoprotein cholesterol (HDL-C) was mea-
sured using two methods, heparin-manganese precipita-
tion and direct immunoassay, depending on participant
age and specimen volume. From 2003, all HDL-C mea-
surements used the direct immunoassay method. Trigly-
cerides were measured after hydrolysis to glycerol. LDL-
C levels were calculated from measurements of total
cholesterol, triglycerides (≤4.52 mmol/L [400 mg/dL]),
and HDL-C according to the Friedewald calculation.
Non-HDL-C was calculated as total cholesterol minus
HDL-C. Plasma glucose was measured using a modified
hexokinase enzymatic method.
Definition of treatment goals
Participants were classified as meeting current LDL-C
and BP treatment goals for patients with diabetes [4] if
their LDL-C level was <2.59 mmol/L (100 mg/dL) or
their BP was ≤130/80 mmHg. In a subset of participants
with a history of CVD, attainment of the optional LDL-
C goal of <1.81 mmol/L (70 mg/dL) was also examined.
In addition, attainment of the secondary lipid goals of
an HDL-C level >1.04 mmol/L (40 mg/dL) in men or
>1.30 mmol/L (50 mg/dL) in women, and a non-HDL-C
level <3.37 mmol/L (130 mg/dL), were also assessed.
Statistical methods
Statistical analyses were performed using SAS software
version 9.2 (SAS Institute Inc., Cary, North Carolina). Esti-
mated population prevalences with P-values were calcu-
lated using the SURVEYFREQ, SURVEYLOGISTIC, and
SURVEYREG procedures in SAS, and were standardized
to the July 2008 U.S. census population ≥20 years of age
(n = 221,419,638). NHANES fasting sample weights were
used and estimates obtained are representative of the U.S.
population. Statistical tests assessing linear trends over the
five 2-year survey cycles were 2-sided and a P-value < 0.05
was considered statistically significant.
Results
Prevalence of diabetes
The prevalence of diagnosed or undiagnosed diabetes in
NHANES during the period from 1999 to 2008 is pre-
sented in Figure 1 by 2-year survey cycle. Diabetes pre-
valence increased significantly over the 5 NHANES
study cycles, from 7.4% in 1999-2000 to 11.9% in 2007-
2008 (P = 0.0007).
Characteristics of participants with diabetes
The demographic and clinical characteristics of 1999-
2008 NHANES participants with diabetes are shown in
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diagnosis of diabetes (75.1% in 2007-2008). Compared
with the 1999-2000 diabetic cohort, participants with
diabetes in the 2007-2008 survey were older (60.0 vs
55.4 years; P = 0.0146), had lower systolic (129.7 vs
130.8 mmHg; P = 0.0198) and diastolic (68.7 vs 71.5
mmHg; P < 0.0001) BP levels, lower total cholesterol
(4.7 vs 5.2 mmol/L [180.6 vs 201.7 mg/dL]; P = 0.0001),
LDL-C (2.6 vs 3.2 mmol/L [102.3 vs 121.9 mg/dL]; P <
0.0001), and triglyceride (1.6 vs 2.1 mmol/L [145.8 vs
186.7 mg/dL]; P = 0.0285) levels, and a higher HDL-C
level (1.3 vs 1.1 mmol/L [49.2 vs 42.6 mg/dL]; P <
0.0001). Although a statistically significant increase in
body mass index was observed in the 2007-2008 versus
1999-2000 cohort (32.0 vs 31.9 kg/m
2; P = 0.0072), such
a small numerical increase is likely to be of limited clini-
cal significance even at a population level. Participants
in the most recent survey cycle were also more likely to
be taking antidiabetic medications (66.2% vs 40.3%; P <
0.0001), as well as medications for hypercholesterolemia
and hypertension (discussed below). CVD burden
was greater in the 2007-2008 cohort versus the 1999-
2000 cohort, most notably for stroke (9.3% vs 3.5%; P =
0.0104).
Lipid control in participants with diabetes
D u r i n gt h es u r v e yp e r i o de x a m i n e d ,t h e r ew a sas i g n i f i -
cant increase in the self-reported use of lipid-lowering
agents by participants with diabetes, from 19.5% in
1999-2000 to 42.2% in 2007-2008 (P <0 . 0 0 0 1 ;T a b l e1 ) .
Over the same time frame, the proportion of partici-
pants achieving the LDL-C goal of <2.59 mmol/L (100
mg/dL) also increased significantly, from 29.7% to 54.4%
(P < 0.0001; Figure 2A). In the subset of diabetic partici-
pants with a history of CVD, attainment of the optional
LDL-C goal of <1.81 mmol/L (70 mg/dL) increased
from 0.7% in 1999-2000 to 28.6% in 2007-2008 (P <
0.0001; Figure 2B). An analysis of the proportion of par-
ticipants with diabetes achieving the secondary lipid
goal of an HDL-C level >1.04 mmol/L (40 mg/dL) in
men or >1.30 mmol/L (50 mg/dL) in women revealed
an increase from 34.5% to 63.9% over the study period
(P < 0.0001; Figure 2C). Attainment of a non-HDL-C
goal of <3.37 mmol/L (130 mg/dL) increased from
21.4% in 1999-2000 to 46.2% in 2007-2008 (P < 0.0001;
Figure 2D).
BP control in participants with diabetes
The self-reported use of antihypertensive agents by par-
ticipants with diabetes increased significantly over the 5
study cycles, from 35.4% in 1999-2000 to 58.9% in 2007-
2008 (P < 0.0001; Table 1). However, despite the
increased utilization of BP-lowering medications over
time, there was no significant change in the proportion
of participants achieving the BP goal of ≤130/80 mmHg
(47.6% in 1999-2000; 55.1% in 2007-2008; P = 0.1333;
Figure 2E) or the prevalence of hypertension (which
increased from 66.6% to 74.2%; P = 0.3724; Table 1).
Dual LDL-C and BP goal attainment in participants with
diabetes
The proportion of participants with diabetes who simul-
taneously achieved both an LDL-C <2.59 mmol/L (100
mg/dL) and a BP ≤130/80 mmHg increased significantly
over the survey period, from 14.7% in 1999-2000 to
28.6% in 2007-2008 (P = 0.0064; Figure 2F).
Discussion
This analysis of 1999-2008 NHANES data has revealed
that the prevalence of diabetes among U.S. adults
increased significantly over the past decade. In 2007-
2008, 11.9% of participants ≥20 years of age had either
diagnosed or undiagnosed diabetes, representing an esti-
mated 26.4 million Americans. Concomitant with the
rise in diabetes prevalence was an increase in the utiliza-
tion of lipid-lowering and antihypertensive medications
in these individuals. Although there was a significant
improvement in LDL-C goal attainment rates over the
10-year period, the proportion of participants at BP goal
remained relatively stable, as did the prevalence of
h y p e r t e n s i o n .H e n c e ,d e s p i te the observed increase in
the pharmacological treatment of CV risk factors within
these high-risk individuals, nearly one-half of the U.S.
diabetic population is currently not at recommended
LDL-C or BP therapeutic goals. Moreover, only ~1 in 4
people with diabetes are achieving both the LDL-C and
BP treatment targets simultaneously, with a similar
Figure 1 Prevalence of diabetes in NHANES, 1999-2008.
Diabetes was identified by self report, self-reported use of insulin or
oral medications for diabetes, or fasting glucose ≥6.99 mmol/L (126
mg/dL).
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very high risk of future CV events (those with a history
of CVD) reaching the more stringent LDL-C goal of
<1.81 mmol/L (70 mg/dL).
These latest estimates of diabetes prevalence and CV
risk factor control in the U.S. diabetic population extend
upon previous reports derived from NHANES data to
2006. Data from NHANES I (1971 to 1975), NHANES
II (1976 to 1980), NHANES III (1988 to 1994), and
NHANES 1999 to 2004 showed a linearly decreasing
trend of participants who reported not having been
diagnosed with diabetes [19]. For the period 2005-2006,
one analysis estimated that 12.9% of U.S. adults had dia-
betes, which included diagnosed diabetes and undiag-
nosed diabetes based on either an oral glucose tolerance
test or fasting plasma glucose [2]. The prevalence of
diabetes based on diagnosis or fasting plasma glucose
only, which is more in line with the criteria for diabetes
used in this current analysis, was ~10%. Another study,
which included only individuals with diagnosed diabetes,
found a prevalence rate for 2003-2006 of 7.8% [20].
Recent analyses of NHANES data suggest that, based on
fasting plasma glucose levels, an additional 2%-3% of the
U.S. population have undiagnosed diabetes [2,3,21]. Our
extended analysis has shown that diabetes prevalence
has increased by nearly 2% in the past 4 years, from
10.2% in 2005-2006 to 11.9% in 2007-2008, an increase
of ~4.3 million people. Previous increases in diabetes
prevalence rates have been driven by a rise in diagnosed
diabetes, with the prevalence of undiagnosed diabetes
remaining stable [2,21], and may be attributable to
increased awareness of the condition among healthcare
Table 1 Characteristics of NHANES participants with diabetes*, 1999-2008
1999-2000
(n = 149)
2001-2002
(n = 220)
2003-2004
(n = 209)
2005-2006
(n = 240)
2007-2008
(n = 396)
Characteristic n Value n Value n Value n Value n Value P†
Diabetes diagnosed (%) 98 70.3 (5.0) 144 69.2 (4.1) 158 72.0 (3.6) 182 73.0 (3.9) 303 75.1 (2.1) 0.2203
Age at screening (years) 149 55.4 (1.7) 220 57.0 (1.2) 209 59.1 (1.8) 240 59.2 (1.3) 396 60.0 (0.8) 0.0146
Male (%) 70 52.7 (4.3) 124 58.4 (4.2) 112 56.3 (3.6) 120 45.0 (4.5) 204 52.2 (3.2) 0.2156
Race/ethnicity (%) 0.9490
Non-Hispanic white 51 66.5 (6.8) 100 65.3 (5.3) 93 66.9 (7.5) 104 66.0 (5.6) 179 66.7 (5.6)
Non-Hispanic black 30 11.9 (2.6) 46 13.9 (2.2) 40 13.0 (3.6) 75 16.7 (3.0) 91 16.0 (3.9)
Mexican American 53 6.4 (1.9) 56 6.5 (1.2) 61 8.4 (3.8) 52 9.9 (2.0) 70 8.4 (2.4)
Other 15 15.2 (7.4) 18 14.3 (5.3) 15 11.6 (3.5) 9 7.4 (2.8) 56 8.9 (2.6)
Body mass index (kg/m
2) 148 31.9 (1.1) 208 31.9 (1.1) 203 31.0 (0.7) 234 33.4 (0.5) 383 32.0 (0.5) 0.0072
Blood pressure (mmHg)
Systolic 149 130.8 (1.3) 220 131.8 (1.5) 209 129.5 (2.0) 240 130.5 (1.7) 396 129.7 (1.4) 0.0198
Diastolic 149 71.5 (2.1) 220 71.7 (1.4) 209 69.1 (1.4) 240 68.1 (1.2) 396 68.7 (0.9) <0.0001
Total cholesterol (mg/dL) 149 201.7 (4.1) 220 195.6 (2.6) 209 198.3 (3.2) 240 191.4 (3.5) 396 180.6 (2.6) 0.0001
LDL cholesterol (mg/dL) 149 121.9 (3.1) 220 116.6 (2.1) 209 114.3 (2.9) 240 107.4 (2.6) 396 102.3 (2.3) <0.0001
HDL cholesterol (mg/dL) 149 42.6 (1.3) 220 48.0 (1.6) 209 49.8 (1.4) 240 52.4 (1.6) 396 49.2 (0.8) <0.0001
Triglycerides (mg/dL) 149 186.7 (8.3) 220 155.5 (4.6) 209 170.6 (9.2) 240 157.7 (5.7) 396 145.8 (2.9) 0.0285
Medication use (%)‡
Antidiabetics§ 72 40.3 (7.6) 113 52.2 (4.0) 125 53.4 (4.0) 166 65.9 (4.0) 268 66.2 (2.8) <0.0001
Antihyperlipidemics║ 31 19.5 (3.9) 54 23.9 (3.8) 81 42.4 (3.5) 97 40.6 (4.3) 163 42.2 (3.6) <0.0001
Antihypertensives¶ 63 35.4 (5.4) 114 46.2 (4.3) 116 49.6 (3.5) 145 59.7 (2.7) 236 58.9 (3.1) <0.0001
Cardiovascular disease history (%)‡
Coronary heart disease# 26 15.4 (4.7) 38 12.9 (2.4) 37 18.6 (4.9) 42 16.0 (1.9) 79 20.9 (2.3) 0.1603
Congestive heart failure 9 5.8 (2.8) 17 5.3 (1.4) 15 6.4 (2.5) 24 9.4 (1.7) 36 9.0 (1.8) 0.1314
Stroke 4 3.5 (2.3) 11 3.9 (1.4) 18 8.3 (2.1) 31 11.7 (3.5) 39 9.3 (2.2) 0.0104
Hypertension (%)** 109 66.6 (7.2) 176 76.4 (2.5) 155 69.4 (4.3) 188 75.5 (2.9) 307 74.2 (2.6) 0.3724
Values are weighted percent (standard error) or mean (standard error). Estimates were standardized to the July 2008 U.S. census population ≥20 years of age.
To convert total cholesterol, LDL cholesterol, HDL cholesterol from mg/dL to mmol/L, multiply by 0.0259; to convert triglycerides from mg/dL to mmol/L, multiply
by 0.0113.
*Diabetes was identified by self report, self-reported use of insulin or oral medications for diabetes, or fasting glucose ≥6.99 mmol/L (126 mg/dL). †P values are
for 1999-2000 versus 2007-2008; P value for race/ethnicity compares the distribution of race/ethnicity categories. ‡All drug utilization and disease history was
self-reported. §Any antidiabetic agents including insulin and oral medications for diabetes. ║Any lipid-lowering agents including statins, fibric acid derivatives,
bile acid sequestrants, cholesterol absorption inhibitors, and other antihyperlipidemic agents. ¶Any antihypertensive agents including b-blockers, calcium channel
blockers, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and other BP-lowering agents. #Coronary heart disease was identified
by self report of heart disease, angina, or myocardial infarction. **Hypertension was defined as an average BP >130 mmHg systolic or >80 mmHg diastolic, or
self-reported use of antihypertensive agents.
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Page 4 of 9Figure 2 Lipid and BP Goal Attainment in NHANES participants with diabetes, 1999-2008. A: Proportion of participants at LDL-C goal
<2.59 mmol/L (100 mg/dL). B: Proportion of participants with CVD history at LDL-C goal <1.81 mmol/L (70 mg/dL). CVD was identified by self
report of CHD, congestive heart failure, or stroke; CHD was identified by self report of heart disease, angina, or myocardial infarction. C:
Proportion of participants at HDL-C goal >1.04 mmol/L (40 mg/dL, in males, “M”) or >1.30 mmol/L (50 mg/dL, in females, “F”). D: Proportion of
participants at non-HDL-C goal <3.37 mmol/L (130 mg/dL). E: Proportion of participants at BP goal ≤130/80 mmHg. F: Dual LDL-C (<2.59 mmol/L
[100 mg/dL]) and BP (≤130/80 mmHg) goal attainment. To convert total cholesterol, LDL-C, HDL-C, and non-HDL-C from mg/dL to mmol/L,
multiply by 0.0259.
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Page 5 of 9professionals and the general public. However, this ana-
lysis has shown that around one-quarter of diabetes in
the U.S. adult population is currently undiagnosed, indi-
cating the potential for further improvement in the
recognition of diabetes and its associated risk factors.
Few studies have examined LDL-C goal attainment in
the general U.S. diabetic population [20,22], with most
assessing the achievement of a total cholesterol target of
<5.18 mmol/L (200 mg/dL) [22-24]. An analysis of data
from NHANES 1988-1994 (NHANES III) and NHANES
1999-2002, in addition to Behavioral Risk Factor Surveil-
lance System data from 1995 and 2002, found a substan-
tial increase in the proportion of the adult diabetic
population achieving the less-stringent LDL-C target of
<3.37 mmol/L (130 mg/dL) between the baseline surveys
(42.4%) and later surveys (64.2%); an LDL-C <2.59
mmol/L (100 mg/dL) was attained in 10.8% and 33.8%
of participants with diabetes, respectively [22]. Estimates
from more recent NHANES study cycles found that the
proportion of adults with diagnosed diabetes achieving
an LDL-C target of <2.59 mmol/L (100 mg/dL)
increased significantly, from 36.1% in 1999-2002 to
46.5% in 2003-2006 [20]. Our results indicate that this
positive trend in LDL-C goal attainment among U.S.
adults with diabetes is continuing, with around half
(54.4%) of this population achieving the therapeutic tar-
get in 2007-2008.
The same cannot be said of BP goal attainment.
Almost without exception [24], previous analyses of
national population-based data sets have reported a lack
of significant improvement in BP control over time in
those with diagnosed diabetes [20,22,23]. Although we
observed a numerical increase (to 55.1%) in the propor-
tion of U.S. diabetic individuals with a BP ≤130/80
mmHg, the overall trend in BP goal attainment over the
10-year period was not significant.
Undertreatment of dyslipidemia in patients with diabetes
Despite an observed increase in the use of lipid-lowering
agents by the U.S. diabetic population over the survey
period, in the most recent study cycle (2007-2008) less
than one-half (42.2%) of these high-risk individuals
reported taking some form of lipid-modifying therapy,
and just over one-half (54.4%) were achieving the LDL-
C goal recommended by current national treatment
guidelines for diabetes. Undertreatment of dyslipidemia
in diabetes has also been reported in the real-world clin-
ical setting: a recent evaluation of the pharmacological
treatment of mixed dyslipidemia (suboptimal LDL-C,
HDL-C, and/or triglyceride levels) in diabetic patients
from a large U.S. managed healthcare plan found that
>40% received no lipid-lowering therapy even after sub-
optimal lipid values were obtained [25]. Underutilization
of lipid-lowering drugs in patients with diabetes is not
restricted to the U.S. but is a global problem that also
affects Europe [e.g. ref. [26]] and Asia [e.g. ref. [27]]. An
analysis of the German DUTY diabetes registry found
that just 24% of primary prevention patients and 46% of
secondary prevention patients received lipid-lowering
therapy [26]. Similarly, lipid-lowering therapy was pre-
scribed in only ~29% of Chinese diabetic patients in a
prospective cohort analysis of the Hong Kong Diabetes
Registry [27].
Numerous factors likely contribute to the gap between
treatment recommendations for CV risk management in
diabetes and real-world clinical settings. For example,
while LDL-C-targeted statin therapy is advocated for the
pharmacological management of dyslipidemia in patients
with diabetes [4], many U.S. physicians hold falsely ele-
vated concerns about the perceived risk of hepatotoxi-
city that prevent statin prescription in patients with a
clinical indication for their use [28]. Such concerns are
not supported by current evidence from randomized
trials and meta-analyses demonstrating the safety and
tolerability of statin therapy, particularly in patients with
diabetes [10-13,29], and recommendations to discon-
tinue the routine monitoring of liver function tests in
statin-treated patients [30].
Reducing CV risk in diabetes: evidence from randomized
controlled trials
Although suboptimal management of CV risk factors
persists in U.S. adults with diabetes, the observed
increases in the use of lipid-lowering agents and LDL-C
goal attainment, particularly in the latter half of the past
decade, may correspond to the publication of several
large CV outcomes trials supporting the use of statins in
this high-risk population. In 2003, a subgroup analysis
of patients with diabetes enrolled in the Heart Protec-
tion Study (HPS) [10] reported that treatment with sim-
vastatin reduced the relative risk of first major CV
events by 22%. Reductions in relative risk of up to one-
third were observed in diabetic patients without a diag-
nosis of CHD at study entry and/or whose pretreatment
LDL-C level was <3.00 mmol/L (116 mg/dL) [10], sug-
gesting that lipid-lowering therapy is beneficial for
patients with diabetes even in the absence of overt CHD
or elevated lipid levels. The 2004 publication of the Col-
laborative Atorvastatin Diabetes Study (CARDS) [11],
which investigated the effectiveness of atorvastatin for
primary prevention of CV events in patients with dia-
betes and baseline LDL-C levels ~3.03 mmol/L (117
mg/dL), reinforced this notion. Randomization to ator-
vastatin was associated with a 37% reduction in the rela-
tive risk of major CV events; the relative risk of stroke
was reduced by 48% [11]. More recent subgroup ana-
lyses from other large statin trials, such as the Anglo-
Scandinavian Cardiac Outcomes Trial-Lipid-Lowering
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gets (TNT) study [13], have continued to provide evi-
dence on the benefits of statin therapy in reducing CV
complications in diabetic individuals.
Similarly, CV outcomes trials of antihypertensive
agents demonstrating the clinical benefit of aggressive
treatment to BP targets in patients with diabetes may
also have contributed to the significant increase in the
use of BP-lowering medications by this group in the
past decade. In 1998, the U.K. Prospective Diabetes
Study (UKPDS) compared tight control of BP to <150/
85 mmHg versus less-tight control of BP to <180/105
mmHg in hypertensive diabetic patients [14]. The
observed reductions in relative risk in patients allocated
to tight BP control were 24% for diabetes-related end
points (which included sudden death, myocardial infarc-
tion, angina, heart failure, and stroke), 32% for deaths
related to diabetes (which included death due to myo-
cardial infarction, sudden death, stroke, and peripheral
vascular disease), and 44% for stroke [14]. A subgroup
analysis of the diabetic cohort within the Hypertension
Optimal Treatment (HOT) trial, where hypertensive
patients were randomly assigned to a target diastolic BP,
found that the risk of major CV events was halved in
those randomized to ≤80 mmHg versus ≤90 mmHg
[15]. However, while trials such as these have generally
indicated that aggressive BP control is effective in redu-
cing the risk of CV complications of diabetes, recent
results have questioned the clinical benefit of lowering
BP levels to within the normotensive range. The Action
to Control Cardiovascular Risk in Diabetes (ACCORD)
trial, where diabetic patients were targeted to a systolic
BP <120 mmHg versus <140 mmHg, did not demon-
strate a significant reduction in the relative risk of major
CV events but did show a significant reduction in stroke
risk [31]. Similarly, a subgroup analysis from the Inter-
national Verapamil SR-Trandolapril Study (INVEST)
found that, among diabetic patients with CHD, strict
control of systolic BP (<130 mmHg) was not associated
with improved CV outcomes in comparison with usual
control (130 mmHg to <140 mmHg) [32]. Nevertheless,
despite recent debate around intensive BP control, the
finding from our analysis that nearly half of all U.S.
adults with diabetes are not meeting the current recom-
mendations around LDL-C or BP treatment goals is of
concern, and may have serious implications for the
future CVD burden in this population.
Improving quality of care in diabetes
The frontline in the battle to improve therapeutic goal
attainment within the context of diabetes is the pri-
mary-care setting; hence, quality-of-care initiatives must
engage both patients and providers. National awareness
campaigns, such as those by the National Diabetes
Education Program, serve to increase patient under-
standing of CV risk factors and their control through
self-management. Provider recognition programs and
public reporting of performance measures may motivate
healthcare professionals to improve levels of diabetes
care [33]. Other provider-level incentive strategies
designed to enhance patient outcomes include educa-
tional (e.g., continuing medical education credit), practi-
cal (e.g., technical assistance for quality improvement
activities), managerial (e.g., increased autonomy), and
financial (e.g., pay-for-performance) components, which
have been used either alone or in combination by indivi-
dual health plans, employers, and government purcha-
sers with varying degrees of success [33]. The Physicians
Quality Reporting Initiative, implemented by the Centers
for Medicare and Medicaid Services, is a pay-for-partici-
pation program where providers who satisfactorily
report on a set of quality measures earn an incentive
payment, and is viewed by many as a framework for a
nationalized pay-for-performance scheme. An example
of how a government incentive program might improve
evidence-based standards of care in diabetes can be
found in the United Kingdom where, in 2004, the
National Health Service introduced a pay-for-perfor-
mance scheme to reward primary-care practices that
achieve clinical targets for a number of chronic condi-
tions. Substantial improvements in the attainment of BP
(≤145/85 mmHg) and total cholesterol (≤5.05 mmol/L
[195 mg/dL]) goals in patients with diabetes have been
observed since the introduction of the scheme, with as
many as ~80% of patients achieving these (albeit less-
stringent) targets by 2007-2008 [34]. However, further
evaluation is needed to assess the contribution of this
scheme to improvements in care versus underlying posi-
tive trends in quality, as well as the potential for selec-
tive inclusion or exclusion of patients and achievement-
threshold effects [34].
Study limitations
The results of our current analysis should be interpreted
with consideration of the following limitations. Informa-
tion on NHANES participants’ drug utilization and dis-
ease history is derived from self-reported data obtained
through interviews and questionnaires, and as such may
be subject to recall bias. Also, laboratory measurements
of glucose and lipid levels were performed on a single
specimen, and relied on participants self-reporting an
appropriate period of fasting, the absence of which may
confound prevalence estimates and goal attainment
rates. Although current national guidelines for the
assessment of elevated cholesterol levels do not stipulate
repeat testing for lipid measurements [8], the diagnostic
criteria for diabetes recommend that any positive test
result for diabetes in asymptomatic individuals should
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rule out laboratory error [4]. While confirmation of a
diagnosis of diabetes is of vital importance in the clinical
setting, the incremental benefit derived from sequential
testing of plasma glucose levels within an epidemiologi-
cal context is less clear. While encouraging, the positive
trend in HDL-C goal attainment rates must be inter-
preted with caution due to potential bias arising from
the various HDL-C assays employed in NHANES during
this period, despite adjustments made to HDL-C values
to account for this [18]. The low number of participants
with valid data on their diabetic status, in addition to
complete lipid and BP data, in NHANES 1999-2008 lim-
ited the ability to perform and interpret subgroup ana-
lyses of the data. The exclusion of institutionalized
persons in NHANES, such as those residing in long-
term care, may have contributed to the low number of
diabetic participants identified for inclusion in this ana-
lysis. Finally, NHANES data are derived from separate
cross-sectional surveys for each study cycle. Hence,
while trends in prevalence estimates and goal attainment
rates can be inferred from the data, conclusions as to
causality of these temporal relationships are not
possible.
Conclusions
Among the U.S. diabetic population, the proportion of
individuals taking cholesterol- and BP-lowering medica-
tion has increased significantly in the past decade. How-
ever, while there has been a significant improvement in
LDL-C goal attainment rates over time, nearly one-half
of all U.S. adults with diabetes are currently not achiev-
ing LDL-C or BP treatment goals recommended by the
latest clinical practice guidelines. Moreover, only ~1 in
4 people with diabetes are achieving both the LDL-C
and BP treatment targets simultaneously. These nation-
ally representative trends suggest that continued efforts
by healthcare professionals are required to achieve
recommended treatment goals for CV risk factors and
reduce the economic and social burden of CV complica-
tions associated with diabetes.
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